MOUNTAIN VIEW, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, announced today that the first patient has been successfully enrolled in the independent, investigator-led DAME Trial to evaluate the clinical efficacy, safety, cost-effectiveness, and patient acceptability of adding subthreshold MicroPulse treatments ...

Company Overview - Iridex Corporation is a global leader in developing, manufacturing, and marketing innovative laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market [3] - The company's proprietary MicroPulse® technology offers a differentiated laser treatment that is safe, effective, and proven for targeted sight-threatening eye conditions [3] - Iridex's product line is utilized for treating glaucoma, diabetic macular edema (DME), and other retinal diseases [3] - Products are sold in the U.S. through a direct sales force and internationally via a network of independent distributors in over 100 countries [3] Upcoming Financial Results - The company plans to release its financial results for the first quarter of 2025 and provide a business update after the close of trading on May 13, 2025 [1] - A conference call will be hosted by the management team at 2:00 p.m. PT / 5:00 p.m. ET on the same day [2] - Investors can access the conference call by dialing +1-888-596-4144 and using conference ID: 698002, with a live and recorded webcast available on the company's website [2]

Core Insights - Iridex Corporation will host a special call on April 16, 2025, to discuss its strategic vision following a recent investment from Novel [1] - The conference call will begin at 2:00 p.m. PT / 5:00 p.m. ET, and investors can participate by dialing 888-596-4144 with conference ID: 9584140 [2] - Iridex is a leader in developing laser-based medical systems for ophthalmology, focusing on treatments for glaucoma and retinal diseases [3] Company Overview - Iridex Corporation specializes in innovative laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market [3] - The company's proprietary MicroPulse® technology offers a differentiated laser treatment for sight-threatening eye conditions [3] - Iridex's products are marketed in over 100 countries, with a direct sales force in the United States and independent distributors internationally [3]